Betamethasone / Calcipotriol: 4 agencies, 2008–2025
This page collects every recorded health technology assessment decision for one molecule across the agencies in our archive, and compares them. The comparison is the point: each agency publishes its own verdict, none publishes how that verdict sits against the others.
What the record shows
The file has been open for more than a decade: 17 years separate the first record, 23 Jul 2008 at PHARMAC (New Zealand), from the most recent, 2025 at PBAC (Australia).
PBAC (Australia) changed its position: not recommended in 2023, recommended by 2025, after a resubmission.
No assessment is on file from HAS (France), TLV (Sweden), CIPM (Spain) and G-BA (Germany), each among the eight highest-volume agencies here.
The file is active: 3 of 7 records date from 2023 or later.
3 distinct indication wordings are recorded for betamethasone / calcipotriol by the agencies that label one in English (AWMSG, PBAC and SMC).
3 of these 7 records carry a year of decision but no day, so any interval quoted here is approximate to within a year.
PHARMAC (New Zealand) was first to assess betamethasone / calcipotriol, on 23 Jul 2008; PBAC (Australia) did not open a file until 2023 — an unusually long tail of 15 years between the earliest and latest system to look at it.
2 of the 4 agencies here assessed betamethasone / calcipotriol more than once, PBAC (Australia) most often at 3 entries — repeat review is the norm for this molecule rather than the exception.
Coverage is narrow: only 4 of the 18 agencies here have assessed betamethasone / calcipotriol.
The full ledger for betamethasone / calcipotriol reads 4 recommended, 2 not assessed and 1 not recommended.
Decisions on file
| Agency | Date | Indication as recorded | Outcome | Source |
|---|---|---|---|---|
| PBAC (Australia) | 2025 | Chronic stable plaque type psoriasis vulgaris | Recommended | source |
| AWMSG (Wales) | 3 Sep 2021 | Topical treatment of mild to moderate psoriasis vulgaris, including scalp psoriasis, in adults | outside AWMSG criteria | source |
| SMC (Scotland) | 12 Sep 2016 | Topical treatment of psoriasis vulgaris in adults. | accepted | source |
| AWMSG (Wales) | 25 Feb 2016 | Topical treatment of psoriasis vulgaris in adults | outside AWMSG criteria | source |
| PHARMAC (New Zealand) | 23 Jul 2008 | Psoriasis | PTAC advice: Cost Neutral · decision reached | source |
2 further decisions for betamethasone / calcipotriol, across 1 agency, are not shown here.
Related molecules
- budesonide — same ATC class A07E — Antidiarrheals / intestinal anti-inflammatories
- mesalazine — same ATC class A07E — Antidiarrheals / intestinal anti-inflammatories
- beclometasone — same ATC class A07E — Antidiarrheals / intestinal anti-inflammatories
- beclometasone / formoterol — same ATC class A07E — Antidiarrheals / intestinal anti-inflammatories
- beclometasone / formoterol / glycopyrronium — same ATC class A07E — Antidiarrheals / intestinal anti-inflammatories
- prednisolone — same ATC class A07E — Antidiarrheals / intestinal anti-inflammatories
Coverage: 7 decisions for betamethasone / calcipotriol from 4 agencies, 2008 to 2025. Data to 7 Sep 2026. ATC class A07E — Antidiarrheals / intestinal anti-inflammatories. How this page is produced. Compiled by Altima Partners; queries: sales@altimapartners.co.uk.